Verify three factors: peptide reconstitution clarity (incomplete dissolution means underdosing), UV exposure timing (injecting without UV within 24 hours wastes the dose), and UV intensity (40% MED is subtherapeutic for most skin types)
doi: 10.3389/fcell.2023.1291686 Received 10 September 2023 Accepted 22 November 2023 Published 06 December 2023 Volume 11 - 2023 Edited by Parameswaran Ramakrishnan, Case Western Reserve University, United States Reviewed by Neha Nanda, Harvard Medical School, United States Jacopo Di Gregorio, University of LAquila, Italy Updates Copyright 2023 Deng, Jia, Ming, Sun, Lu, Liu and Zhou
The trials were well-designed, the results compelling
Current therapeutic approachesincluding supraphysiologic insulin( 19 ), insulin sensitizers( 20 ), leptin( 21, 22 ), and insulin-like growth factor-1 (IGF-1)( 2329 )provide limited metabolic benefit and do not correct the underlying receptor signaling defect
In some cases, alternative treatments that do not carry the same risks, such as non-hormonal medications or lifestyle modifications, may be more appropriate
For example, microdose GLP-1 protocol ($129/mo flat) delivers a gentler entry into semaglutide therapy, which can reduce the intensity of all early side effects, including sweating